mTORC1-dependent AMD1 regulation sustains polyamine metabolism in prostate cancer
Amaia Zabala‐Letona(CIC bioGUNE), Amaia Arruabarrena-Aristorena(CIC bioGUNE), Natalia Martín-Martín(CIC bioGUNE), Sonia Fernández‐Ruiz(Centro de Investigación Biomédica en Red de Cáncer), James D. Sutherland(CIC bioGUNE), Michelle Clasquin(Agios Pharmaceuticals (United States)), Julen Tomás‐Cortázar(CIC bioGUNE), José Jiménez(Universitat Autònoma de Barcelona), Ines Torres(Universitat Autònoma de Barcelona), Phong Quang(Agios Pharmaceuticals (United States)), Pilar Ximénez‐Embún(Spanish National Cancer Research Centre), Ružica Bago(University of Dundee), Aitziber Ugalde‐Olano(Hospital de Basurto), Ana Loizaga‐Iriarte(Hospital de Basurto), Isabel Lacasa-Viscasillas(Hospital de Basurto), Miguel Unda(Hospital de Basurto), Verónica Torrano(Centro de Investigación Biomédica en Red de Cáncer), Diana Cabrera(CIC bioGUNE), Sebastiaan van Liempd(CIC bioGUNE), Ylenia Cendón(Spanish National Cancer Research Centre), Elena Castro(Spanish National Cancer Research Centre), Stuart Murray(Agios Pharmaceuticals (United States)), Ajinkya Revandkar(Institute of Oncology Research), Andrea Alimonti(Institute of Oncology Research), Yinan Zhang(Harvard University), Amelia Barnett(Agios Pharmaceuticals (United States)), Gina Lein(Agios Pharmaceuticals (United States)), David Pirman(Agios Pharmaceuticals (United States)), Ana R. Cortázar(CIC bioGUNE), Leire Arreal(CIC bioGUNE), Ludmila Prudkin(Universitat Autònoma de Barcelona), Ianire Astobiza(CIC bioGUNE), Lorea Valcárcel-Jiménez(CIC bioGUNE), Patricia Zúñiga-García(CIC bioGUNE), Itziar Fernández-Domínguez(CIC bioGUNE), Marco Piva(CIC bioGUNE), Alfredo Caro‐Maldonado(CIC bioGUNE), Pilar Sánchez‐Mosquera(CIC bioGUNE), Mireia Castillo-Martín(Champalimaud Foundation), Violeta Serra(Instituto de Salud Carlos III), Naiara Beraza(CIC bioGUNE), Antonio Gentilella(Institut Català d'Oncologia), George Thomas(Institut Català d'Oncologia), Mikel Azkargorta(Instituto de Salud Carlos III), Félix Elortza(Instituto de Salud Carlos III), Rosa Farrás(Centro de Investigacion Principe Felipe), David Olmos(Spanish National Cancer Research Centre), Alejo Efeyan(Spanish National Cancer Research Centre), Juan Anguíta(CIC bioGUNE), Javier Muñoz(Spanish National Cancer Research Centre), Juan Manuel Falcón‐Pérez(Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas), Rosa Barrio(CIC bioGUNE), Teresa Macarulla(Universitat Autònoma de Barcelona), José M. Mato(Instituto de Salud Carlos III), Maria Luz Martínez‐Chantar(Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas), Carlos Cordon‐Cardo(Icahn School of Medicine at Mount Sinai), Ana M. Aransay(Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas), Kevin M. Marks(Agios Pharmaceuticals (United States)), José Baselga(Memorial Sloan Kettering Cancer Center), Josep Tabernero(Centro de Investigación Biomédica en Red de Cáncer), Paolo Nucíforo(Universitat Autònoma de Barcelona), Brendan D. Manning(Harvard University), Katya Marjon(Agios Pharmaceuticals (United States)), Arkaitz Carracedo(University of the Basque Country)
Cited by 215Open Access
Abstract
Related Papers
No related papers found
Powered by citation graph analysis